What is the projected market valuation for the Neuroblastoma Market in 2035?

The projected market valuation for the Neuroblastoma Market in 2035 is 559.08 USD Million. Read More

What was the overall market valuation for the Neuroblastoma Market in 2024?

The overall market valuation for the Neuroblastoma Market in 2024 was 386.95 USD Million. Read More

What is the expected CAGR for the Neuroblastoma Market during the forecast period 2025 - 2035?

The expected CAGR for the Neuroblastoma Market during the forecast period 2025 - 2035 is 3.4%. Read More

Which treatment type generated the highest revenue in the Neuroblastoma Market?

Chemotherapy generated the highest revenue in the Neuroblastoma Market, with a valuation range of 150.0 to 220.0 USD Million. Read More

How does the revenue from immunotherapy compare to other treatment types in the Neuroblastoma Market?

Immunotherapy generated revenue between 86.95 and 119.08 USD Million, which is lower than chemotherapy but higher than surgery. Read More

What revenue range is expected for localized neuroblastoma treatment by 2035?

The revenue range for localized neuroblastoma treatment is projected to be between 150.0 and 220.0 USD Million by 2035. Read More

What is the revenue range for neuroblastoma treatment in adolescents?

The revenue range for neuroblastoma treatment in adolescents is between 86.95 and 124.08 USD Million. Read More

Which diagnostic method is expected to generate the most revenue in the Neuroblastoma Market?

Imaging techniques are expected to generate the most revenue, with a valuation range of 150.0 to 220.0 USD Million. Read More

What is the revenue range for targeted therapy in the Neuroblastoma Market?

Targeted therapy is projected to generate revenue between 150.0 and 220.0 USD Million. Read More

Neuroblastoma Market

Q: What are the key players in the Neuroblastoma Market?

Key players in the Neuroblastoma Market include Bristol Myers Squibb, Roche, Novartis, Pfizer, Eli Lilly and Company, AstraZeneca, Merck & Co., Amgen, and Bayer. Read More

ID: MRFR/HC/5093-HCR

200 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Neuroblastoma Market Research Report By Treatment Type (Chemotherapy, Surgery, Radiation Therapy, Immunotherapy), By End-user (Hospitals, Specialized Cancer Treatment Centers, Research Institutions), By Disease Stage (Localized Neuroblastoma, Metastatic Neuroblastoma, Recurrent Neuroblastoma), By Age Group (Infants, Children, Adolescents), and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Neuroblastoma Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)3.4%

2024 Market Size$ 386.95 Million

2025 Market Size$ 400.11 Million

2035 Market Size$ 559.08 Million

Key Players

Bristol Myers Squibb

Roche

Novartis

Pfizer

Eli Lilly and Company

AstraZeneca

Trends

Emergence of Targeted Therapies
Advancements in Immunotherapy
Shift Towards Personalized Medicine

Opportunities

Market Growth Projections
Rising Awareness and Advocacy
Enhanced Diagnostic Techniques

Summary Table of Contents Segmentation Methodology Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Treatment Type (USD Million)
  1. 4.1.1 Chemotherapy
  2. 4.1.2 Radiation Therapy
  3. 4.1.3 Surgery
  4. 4.1.4 Immunotherapy
2. 4.2 Healthcare, BY Disease Stage (USD Million)
  1. 4.2.1 Localized
  2. 4.2.2 Regional
  3. 4.2.3 Metastatic
3. 4.3 Healthcare, BY Patient Age Group (USD Million)
  1. 4.3.1 Infants
  2. 4.3.2 Toddlers
  3. 4.3.3 Children
  4. 4.3.4 Adolescents
4. 4.4 Healthcare, BY Diagnosis Method (USD Million)
  1. 4.4.1 Imaging Techniques
  2. 4.4.2 Biopsy
  3. 4.4.3 Blood Tests
5. 4.5 Healthcare, BY Therapeutic Approach (USD Million)
  1. 4.5.1 Targeted Therapy
  2. 4.5.2 Stem Cell Transplantation
  3. 4.5.3 Supportive Care
6. 4.6 Healthcare, BY Region (USD Million)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bristol Myers Squibb (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Roche (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Novartis (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Pfizer (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Eli Lilly and Company (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Merck & Co. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Amgen (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Bayer (DE)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 US MARKET ANALYSIS BY DISEASE STAGE
5. 6.5 US MARKET ANALYSIS BY PATIENT AGE GROUP
6. 6.6 US MARKET ANALYSIS BY DIAGNOSIS METHOD
7. 6.7 US MARKET ANALYSIS BY THERAPEUTIC APPROACH
8. 6.8 CANADA MARKET ANALYSIS BY TREATMENT TYPE
9. 6.9 CANADA MARKET ANALYSIS BY DISEASE STAGE
10. 6.10 CANADA MARKET ANALYSIS BY PATIENT AGE GROUP
11. 6.11 CANADA MARKET ANALYSIS BY DIAGNOSIS METHOD
12. 6.12 CANADA MARKET ANALYSIS BY THERAPEUTIC APPROACH
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY DISEASE STAGE
16. 6.16 GERMANY MARKET ANALYSIS BY PATIENT AGE GROUP
17. 6.17 GERMANY MARKET ANALYSIS BY DIAGNOSIS METHOD
18. 6.18 GERMANY MARKET ANALYSIS BY THERAPEUTIC APPROACH
19. 6.19 UK MARKET ANALYSIS BY TREATMENT TYPE
20. 6.20 UK MARKET ANALYSIS BY DISEASE STAGE
21. 6.21 UK MARKET ANALYSIS BY PATIENT AGE GROUP
22. 6.22 UK MARKET ANALYSIS BY DIAGNOSIS METHOD
23. 6.23 UK MARKET ANALYSIS BY THERAPEUTIC APPROACH
24. 6.24 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
25. 6.25 FRANCE MARKET ANALYSIS BY DISEASE STAGE
26. 6.26 FRANCE MARKET ANALYSIS BY PATIENT AGE GROUP
27. 6.27 FRANCE MARKET ANALYSIS BY DIAGNOSIS METHOD
28. 6.28 FRANCE MARKET ANALYSIS BY THERAPEUTIC APPROACH
29. 6.29 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
30. 6.30 RUSSIA MARKET ANALYSIS BY DISEASE STAGE
31. 6.31 RUSSIA MARKET ANALYSIS BY PATIENT AGE GROUP
32. 6.32 RUSSIA MARKET ANALYSIS BY DIAGNOSIS METHOD
33. 6.33 RUSSIA MARKET ANALYSIS BY THERAPEUTIC APPROACH
34. 6.34 ITALY MARKET ANALYSIS BY TREATMENT TYPE
35. 6.35 ITALY MARKET ANALYSIS BY DISEASE STAGE
36. 6.36 ITALY MARKET ANALYSIS BY PATIENT AGE GROUP
37. 6.37 ITALY MARKET ANALYSIS BY DIAGNOSIS METHOD
38. 6.38 ITALY MARKET ANALYSIS BY THERAPEUTIC APPROACH
39. 6.39 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
40. 6.40 SPAIN MARKET ANALYSIS BY DISEASE STAGE
41. 6.41 SPAIN MARKET ANALYSIS BY PATIENT AGE GROUP
42. 6.42 SPAIN MARKET ANALYSIS BY DIAGNOSIS METHOD
43. 6.43 SPAIN MARKET ANALYSIS BY THERAPEUTIC APPROACH
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY DISEASE STAGE
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY PATIENT AGE GROUP
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS METHOD
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC APPROACH
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY TREATMENT TYPE
51. 6.51 CHINA MARKET ANALYSIS BY DISEASE STAGE
52. 6.52 CHINA MARKET ANALYSIS BY PATIENT AGE GROUP
53. 6.53 CHINA MARKET ANALYSIS BY DIAGNOSIS METHOD
54. 6.54 CHINA MARKET ANALYSIS BY THERAPEUTIC APPROACH
55. 6.55 INDIA MARKET ANALYSIS BY TREATMENT TYPE
56. 6.56 INDIA MARKET ANALYSIS BY DISEASE STAGE
57. 6.57 INDIA MARKET ANALYSIS BY PATIENT AGE GROUP
58. 6.58 INDIA MARKET ANALYSIS BY DIAGNOSIS METHOD
59. 6.59 INDIA MARKET ANALYSIS BY THERAPEUTIC APPROACH
60. 6.60 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
61. 6.61 JAPAN MARKET ANALYSIS BY DISEASE STAGE
62. 6.62 JAPAN MARKET ANALYSIS BY PATIENT AGE GROUP
63. 6.63 JAPAN MARKET ANALYSIS BY DIAGNOSIS METHOD
64. 6.64 JAPAN MARKET ANALYSIS BY THERAPEUTIC APPROACH
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY DISEASE STAGE
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY PATIENT AGE GROUP
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS METHOD
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC APPROACH
70. 6.70 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
71. 6.71 MALAYSIA MARKET ANALYSIS BY DISEASE STAGE
72. 6.72 MALAYSIA MARKET ANALYSIS BY PATIENT AGE GROUP
73. 6.73 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS METHOD
74. 6.74 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC APPROACH
75. 6.75 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
76. 6.76 THAILAND MARKET ANALYSIS BY DISEASE STAGE
77. 6.77 THAILAND MARKET ANALYSIS BY PATIENT AGE GROUP
78. 6.78 THAILAND MARKET ANALYSIS BY DIAGNOSIS METHOD
79. 6.79 THAILAND MARKET ANALYSIS BY THERAPEUTIC APPROACH
80. 6.80 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
81. 6.81 INDONESIA MARKET ANALYSIS BY DISEASE STAGE
82. 6.82 INDONESIA MARKET ANALYSIS BY PATIENT AGE GROUP
83. 6.83 INDONESIA MARKET ANALYSIS BY DIAGNOSIS METHOD
84. 6.84 INDONESIA MARKET ANALYSIS BY THERAPEUTIC APPROACH
85. 6.85 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
86. 6.86 REST OF APAC MARKET ANALYSIS BY DISEASE STAGE
87. 6.87 REST OF APAC MARKET ANALYSIS BY PATIENT AGE GROUP
88. 6.88 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS METHOD
89. 6.89 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC APPROACH
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
92. 6.92 BRAZIL MARKET ANALYSIS BY DISEASE STAGE
93. 6.93 BRAZIL MARKET ANALYSIS BY PATIENT AGE GROUP
94. 6.94 BRAZIL MARKET ANALYSIS BY DIAGNOSIS METHOD
95. 6.95 BRAZIL MARKET ANALYSIS BY THERAPEUTIC APPROACH
96. 6.96 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
97. 6.97 MEXICO MARKET ANALYSIS BY DISEASE STAGE
98. 6.98 MEXICO MARKET ANALYSIS BY PATIENT AGE GROUP
99. 6.99 MEXICO MARKET ANALYSIS BY DIAGNOSIS METHOD
100. 6.100 MEXICO MARKET ANALYSIS BY THERAPEUTIC APPROACH
101. 6.101 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
102. 6.102 ARGENTINA MARKET ANALYSIS BY DISEASE STAGE
103. 6.103 ARGENTINA MARKET ANALYSIS BY PATIENT AGE GROUP
104. 6.104 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS METHOD
105. 6.105 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC APPROACH
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE STAGE
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT AGE GROUP
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS METHOD
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC APPROACH
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY DISEASE STAGE
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY PATIENT AGE GROUP
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS METHOD
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC APPROACH
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY DISEASE STAGE
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY PATIENT AGE GROUP
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS METHOD
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC APPROACH
122. 6.122 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
123. 6.123 REST OF MEA MARKET ANALYSIS BY DISEASE STAGE
124. 6.124 REST OF MEA MARKET ANALYSIS BY PATIENT AGE GROUP
125. 6.125 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS METHOD
126. 6.126 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC APPROACH
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
135. 6.135 HEALTHCARE, BY DISEASE STAGE, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY DISEASE STAGE, 2024 TO 2035 (USD Million)
137. 6.137 HEALTHCARE, BY PATIENT AGE GROUP, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Million)
139. 6.139 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
141. 6.141 HEALTHCARE, BY THERAPEUTIC APPROACH, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY THERAPEUTIC APPROACH, 2024 TO 2035 (USD Million)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.2.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.2.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.2.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.3.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.3.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.3.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.3.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.4.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.4.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.4.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.4.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.5.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.5.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.5.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.5.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.6.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.6.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.6.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.6.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.7.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.7.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.7.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.7.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.8.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.8.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.8.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.8.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.9.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.9.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.9.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.9.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.10.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.10.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.10.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.10.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.11.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.11.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.11.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.11.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.12.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.12.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.12.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.12.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.13.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.13.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.13.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.13.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.14.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.14.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.14.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.14.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.15.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.15.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.15.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.15.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.16.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.16.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.16.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.16.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.17.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.17.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.17.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.17.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.18.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.18.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.18.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.18.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.19.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.19.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.19.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.19.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.20.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.20.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.20.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.20.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.21.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.21.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.21.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.21.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.22.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.22.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.22.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.22.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.23.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.23.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.23.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.23.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.24.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.24.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.24.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.24.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.25.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.25.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.25.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.25.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.26.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.26.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.26.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.26.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.27.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.27.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.27.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.27.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.28.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.28.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.28.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.28.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.29.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.29.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.29.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.29.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.30.2 BY DISEASE STAGE, 2025-2035 (USD Million)
  3. 7.30.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.30.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  5. 7.30.5 BY THERAPEUTIC APPROACH, 2025-2035 (USD Million)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Neuroblastoma Market Segmentation

Neuroblastoma Market By Treatment Type (USD Million, 2025-2035)

Chemotherapy
Radiation Therapy
Surgery
Immunotherapy

Neuroblastoma Market By Disease Stage (USD Million, 2025-2035)

Localized
Regional
Metastatic

Neuroblastoma Market By Patient Age Group (USD Million, 2025-2035)

Infants
Toddlers
Children
Adolescents

Neuroblastoma Market By Diagnosis Method (USD Million, 2025-2035)

Imaging Techniques
Biopsy
Blood Tests

Neuroblastoma Market By Therapeutic Approach (USD Million, 2025-2035)

Targeted Therapy
Stem Cell Transplantation
Supportive Care

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”